NEWRON PHARMACEUTICALS S.P.A. EQS-Adhoc: Newron Receives Fourth Tranche from Financing Agreement with European Investment Bank (EIB)
Transparency directive : regulatory news
|
EQS Group-Ad-hoc: Newron Pharmaceuticals SpA / Key word(s): Financing Ad hoc announcement pursuant to Art. 53 SIX Listing Rules Milan, Italy - September 6, 2021, 5.45 pm CEST - Newron Pharmaceutical S.p.A. ('Newron') (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, announces that it has received Tranche 4 under its financing agreement with the European Investment Bank (EIB) that was signed in October 2018 and comprises up to EUR 40 million, subject to achieving a set of agreed performance criteria. The EIB loan is backed by the European Fund for Strategic Investments (EFSI), the central pillar of the Investment Plan for Europe. Tranche 4 consists of EUR 7.5 million and will primarily be used to support the Company's development programs in diseases of the central nervous system. The first three tranches of the loan totaling EUR 25 million were received by Newron in 2019 and 2020. About Newron Pharmaceuticals For more information UK/Europe Switzerland Germany/Europe USA End of ad hoc announcement |
| Language: | English |
| Company: | Newron Pharmaceuticals SpA |
| Via Antonio Meucci 3 | |
| 20091 Bresso | |
| Italy | |
| E-mail: | info@newron.com |
| Internet: | www.newron.com |
| ISIN: | IT0004147952 |
| Listed: | SIX Swiss Exchange |
| EQS News ID: | 1231559 |
| End of Announcement | EQS Group News Service |
|
|
1231559 06-Sep-2021 CET/CEST